t,-The distribution, retention, and phototoxicity of the sensitizer hematoporphyrin derivative (HPD) were studied following intraperitoneal and direct intraneoplastic injections of the agent into subcutaneous or intracerebral gliosarcomas in rats. Forty-eight hours after intraperitoneal injection, the ratio of tritiated (3H) HPD in subcutaneous tumor:adjacent normal skin was about 1.4:1 and the ratio in tumor:normal brain was 3:1. In contrast, direct injection of 3H-HPD into subcutaneous tumors resulted in tumor:adjacent normal skin concentration ratios of approximately 44:1 and tumor:normal brain ratios of about 61:1. For rats bearing intracerebral gliosarcomas, intraperitoneal administration of 3H-HPD resulted in approximately 1.3-fold sensitization in tumor tissue relative to adjacent edematous brain. In contrast, after direct injection into intracerebral tumors, the tumor:adjacent edematous brain and tumor:skin 3H-HPD ratios were 3:1 and 32:1, respectively. In all cases, 3H-HPD was found in every portion of the tumor, even at a distance from the injection site. For the 3H-HPD doses used in this study, after direct injection both subcutaneous and intracerebral tumor tissue contained about three to four times more 3H-HPD than tumors in rats receiving intraperitoneal 3H-HPD. Both in vitro and in vivo clonogenic assays demonstrated that the photodynamic inactivation of the tumors was significantly greater after direct injection than after intraperitoneal injection.
T HE combination of hematoporphyrin derivative (HPD) and visible light, which has been termed "photoradiation therapy" or "photoirradiation," provides a new tool in tumor therapy? The HPD is preferentially localized and retained within malignant tumor tissues. 9'~~ Upon activation by visible light at the proper wavelength (about 630 nm in most preclinical and clinical cases), HPD develops a cytotoxic interaction by producing primarily singlet oxygen j7 (a shortlived, highly reactive state of diatomic oxygen), as well as superoxide 5 and hydroxyl radicals. 2'6'7 There are few reports of photoirradiation in the neurosurgical literature, 8,z3,jS,~8 but a wider experience has been accumulated in other fields suggesting a complete response in approximately one-third of tumors with various histologies?
Since malignant gliomas spread diffusely into normal brain and reach beyond the boundaries of surgery, photoirradiation offers a unique approach to their treatment. All prior animal and human studies have administered HPD intravenously or intraperitoneally; however, cutaneous phototoxicity 3 and possible accumulation in normal brain tissue, 15 including normal brain vessels, 6 limit parenteral administration of HPD doses to no higher than approximately 5 mg/kg body weight. 3'12 Therefore, we injected a higher concentration of HPD directly into the tumor in a rat glioma model and studied its regional distribution in the tumor as well as in other tissues. We also tested for HPD-sensitized tumor photoinactivation in these rats and compared our results to those rats with intraperitoneal HPD administration.
Hematoporphyrin derivative in rat glioma

Materials and Methods
Animal Preparations
Male CD Fischer rats,* each weighing 125 to 175 gm, were used throughout these experiments. The tumor was induced in rats by intravenous-transplacental delivery of ethyl nitrosourea. The tumor was characterized histologically as a gliosarcoma. Tumor tissue was then explanted and maintained in culture to provide cells for this study. The tumors were then propagated either by subcutaneously injecting 2 x 10 6 cells in 0.25 ml saline or by injecting with a microsyringe 2 x 104 cells in 10 ul saline through a burr hole 1 mm posterior to the coronal suture and 2 mm off midline at a depth of 3 mm. The subcutaneous tumors were measured directly in three diameters (a, b, and c) with a caliper, and the volume (v) was calculated as for an ellipsoid:
4 (a x b • c) V-3 2 For measurement of the intracranial tumors, three tumor-implanted but untreated control animals were sacrificed, and the tumor volume was used as the estimated volume for the remaining animals in that group.
Fluorescence microscopy was initially used to screen the subcutaneous and intracerebral tumors for HPD uptake. For this study, samples were frozen in a cryostat, sectioned to 40 um thickness, and examined with a Zeiss Orthoplan microscope using a 405-nm excitation beam (G405 filter) with a red-fluorescence detection filter (LP590).t Adjacent sections were stained with hematoxylin and eosin for light microscopic examination. However, accurate quantitation could not be determined with this technique. Therefore, tritiumlabeled HPD (3H-HPD)~ was used to determine the concentration in all tissues tested since quantitation was direct and reproducible. Nonradioactive HPDw and 3H-HPD were compared by absorbance and fluorescence spectroscopy and by high-pressure liquid and thin-layer chromatography; 1 they were shown to be identical as previously described. 4 The 3H-HPD had a specific activity of 2.4 mCi/mg, and was mixed with nonradioactive HPD in normal saline to yield a 5 x 10 7 cpm/mg HPD/ml solution. With a No. 27 needle, 1 mg 3H-HPD/cu cm tumor volume in a 0.2-ml solution was injected into the center of each tumor. Control animals were injected with an equivalent volume of normal sterile saline.
In order to compare the results of HPD parenteral injection with those of direct tumor injection, 3H-HPD (10 mg/kg) was injected intraperitoneally into another * CD Fischer rats obtained from Charles River Breeding Laboratories, Kingston, New York.
t Detection filter (LP590) manufactured by Carl Zeiss, Inc., Thornwood, New York.
Tritium-labeled HPD manufactured by New England Nuclear, Boston, Massachusetts.
w Nonradioactive HPD manufactured by Photofrin, Inc., Cheektowaga, New York. group of rats. Another control group of animals received an equal volume of normal saline.
The animals were sacrificed with ether at 24 hours, 48 hours, or 6 days after injection, and the tumors and other tissues were microdissected and wrapped in aluminum foil to protect them from light.
Quantitation of Photosensitizer
For 3H-HPD quantitation, 50-to 150-mg samples of tumor or normal tissue were weighed on a Mettler analytical scale and dissolved in Protosol. 11 When necessary, the samples were bleached with H202, and 10 ml Econofluor[[ was added to the completely dissolved samples, which were then analyzed with a Packard Tri Carb scintillation counter.* The HPD content was calculated from the 3H counts per wet tissue weight and the specific activity of the 3H-HPD:isotope-free HPD mixture. In all cases the results are expressed as the mean value _+ standard deviation. When less than three data points were obtained, no standard deviation is given. The significance was determined by the paired Student t-test.
Photodynamic Inactivation
Photodynamic inactivation was tested with both in vivo and in vitro clonogenic assay systems. In each animal used for this part of the study, tumors were induced subcutaneously in each proximal limb. When the tumors reached 1 cm in diameter (approximately on Day 10), nonradioactive HPD was injected either directly into the tumor or intraperitoneally. Control animals received only intraperitoneal saline injections. The animals were kept in ambient room light, and after 48 hours the tumors were randomly chosen for treatment with laser light. A rhodamine-B dye laser pumped by an argon ion laser was used;t the output at 632 _+ 5 nm was 85 mW. The light was delivered via 400-gin quartz fiberoptics to the center of the tumor, providing 120 joules of energy. Sixty hours after treatment, the tumors were dissected en bloc and a single-cell suspension was prepared using trypsin digestion and trituration with a No. 22 needle.
For the in vivo assay, 2 x l0 6 cells (60% to 75% of which were viable at the time of explant, as determined by trypan blue exclusion) were reinjected subcutaneously into each limb of a second generation of animals; in that way the animals harbored differently treated tumors at randomly chosen limb positions. This method allowed direct comparison of the treated tumors with control tumors within the same animal, thus minimizing differences in tumor growth which could be due to the state of health of an animal or other 1[ Protosol and Econofluor manufactured by New England Nuclear, Boston, Massachusetts.
* Packard Tri Carb scintillation counter manufactured by Packard Instrument Co., Inc., Downers Grove, Illinois.
t Argon ion laser manufactured by Spectra-Physics, Inc., Mountain View, California. For the in vitro assay, 4 x 104 cells of the single-cell suspension were seeded into 60-ram tissue culture plates with Ham's F-10 medium enriched with 10% fetal bovine serum and antibiotics (penicillin 100 IU/ml, amphotericin B 0.25 ~g/ml, and streptomycin 100 #g/ ml). The medium was changed twice weekly. After 10 to 12 days, the cultures were washed, fixed with methanol, and stained with 4% Giemsa, and the number of colonies with more than 50 cells were counted. The number of colonies produced by the treated tumors was divided by the colony count of the control group in order to calculate an in vitro growth index. Thus, a growth index of 0.4 indicated that the treated tumors produced only 40% as many colonies as the control group.
Results
HPD Distribution and Retention
Subcutaneous Tumors. Seven subcutaneous tumors with volumes ranging from 0.5 to 2.0 cu cm in seven animals were injected directly with 1.0 mg 3H-HPD/ cu cm tumor volume. After 48 hours, the tissues were dissected for study and the 3H-HPD content was evaluated. The 3H-HPD content in these directly injected tumors was compared to the 3H-HPD concentration in 16 tumors treated by conventional intraperitoneal injection of 10 mg 3H-HPD/kg body weight. After direct injection, 9.75 _+ 5.58 ug 3H-HPD/gm tumor was found, compared to 2.50 + 1.40 ug 3H-HPD/gm after intraperitoneal injection (Table 1) . After intraperitoneal injection, the 3H-HPD was distributed rather uniformly H. Kostron, et al. (Table 2) . Following intraperitoneal injection, the 3H-HPD concentration was 0.82 + 0.27 #g/gm in the normal brain and 1.85 _+ 0.44 #g/gm in the skin; after direct tumor injection, the 3H-HPD level in normal brain tissue was 0.16 _+ 0.08 #g/gm, and 0.22 _+ 0.08 ug/gm could be detected in the skin (Table 1). The muscle tissue adjacent to the directly injected tumor showed 0.28 ug 3H-HPD/gm, and the contralateral subcutaneous tumors (which had not been injected) had 0.33 _+ 0.05 #g 3H-HPD/gm (Table 2) .
Intracerebral Tumors. Eleven brain tumors of the right temporal lobe, ranging from 3 to 6 mm in diameter, were injected with 1 mg 3H-HPD/cu cm through the same burr hole and with the same syringe apparatus used to instill the tumors. In some animals this induced a temporary state of hyperactivity lasting approximately 5 to 15 minutes but causing no sequelae or permanent morbidity. At various times after injection, some animals were sacrificed and the brains were microdissected. The tissues were weighed, washed with saline, and prepared for scintillation counting and for microscopic studies. At 48 hours after direct injection, the brain tumors contained 3H-HPD concentrations of 6.66 ___ 4.14 ug/gm, whereas the edematous brain adjacent to the tumor contained 2.23 _+ 1.51 ~g 3H-HPD/gm ( Table  3 ). The remaining ipsilateral hemisphere showed an average content of 0.51 + 0.40 ~g 3H-HPD/gm, ranging from 0.93 #g/gm close to the edematous brain to 0.07 ug/gm in the most peripheral areas of the frontal and occipital lobes. The contralateral hemisphere had a 3H-HPD content of 0.12 _ 0.09 #g/gm. Cerebellum, brain stem, and spinal cord (lumbar region) contained 0.07 _+ 0.03, 0.09 + 0.04, and 0.09 + 0.04 #g 3H-HPD/ gm, respectively (Table 3) .
In order to examine the velocity of diffusion and the delayed retention of 3H-HPD, two animals were sacrificed at 24 hours and two animals at 6 days after direct t Significance: p < 0.005 as compared to tissue levels 48 hours after intraperitoneal injection of 10 mg 3H-HPD/kg animal body weight (see Table 4 ). tumor injection. At 24 hours, there was an average 3H-HPD content of 11.25 ug/gm in the tumor, 3.54 ug/gm in the adjacent edematous brain, 3.53 ug/gm in the ipsilateral hemisphere, and 0.83 ug/gm in the contralateral hemisphere (Table 3) . At 6 days, there was an average 3H-HPD concentration of 2.19 ug/gm in the tumor, 0.19 ug/gm in the ipsilateral hemisphere, and 0 ug/gm in the contralateral hemisphere, cerebellum, brain stem, spinal cord, and skin.
These results were contrasted with those obtained 48 hours after intraperitoneal injection of 3H-HPD, which produced 3H-HPD concentrations of 2.35 + 0.70 ug/ gm in the tumor and 1.85 ___ 0.08 ug/gm in the adjacent normal brain (Table 4 ). The 3H-HPD levels in the adjacent edematous brain and ipsilateral hemisphere were not significantly different between the two routes of administration. In contrast, the 3H-HPD content was significantly higher (p < 0.005) in the directly injected tumors than in those receiving intraperitoneal 3H-HPD (compare Tables 3 and 4) .
Direct Injection of Tritiated-HPD into Normal
Brain. Time course studies were performed in tumorfree animals after injection of 50 #g 3H-HPD into normal brain at the same location as the brain tumors in other animals ( Table 5 ). The following mean 3H-HPD values were obtained at the injection site at 24 hours, 48 hours, and 6 days after injection: 10.10, 2.65 _+ 0.58, and 1.49 ug/gm. For the ipsilateral cortex these values were 1.84, 0.89 ___ 0.66, and 0.39 ug 3H-HPD/gm, while the contralateral hemisphere contained 0.96, 0.67 _ 0.29, and 0.01 ug 3H-HPD/gm. The HPD spread readily to the cerebellum (3.25, 2.74, and 0.00 ug/gm), to the brain stem (2.58, 1.98, and 0.00 -t Significance: p < 0.005 as compared to tissue levels 48 hours after direct (intratumoral) injection of 1 mg 3H-HPD/cu cm tumor volume (see Table 3 ). #g/gm), and to the spinal cord (not determined, 2.72, and 0.00 #g/gm). The 3H-HPD values for skin (0.12, 0.21, and 0.00 #g/gm) were similar to those obtained in the tumor-bearing group.
Photodynamic Inactivation
To test for the photodynamic inactivation of the tumors, the subcutaneous gliosarcoma system was used. The inhibition of tumor growth was tested both in vivo and in vitro with a clonogenic assay system.
In the in vivo assay (Table 6 ), the intraperitoneal injection of 10 mg HPD/kg into subcutaneous tumors caused no significant inhibition of tumor growth when the animal was housed in ambient room light and no laser irradiation was used (growth index = 1.33 __. 0.48). The addition of laser energy to these tumors significantly inhibited their growth (growth index = 0.23 +_ 0.06). In contrast, the tt mors that were directly injected with HPD demonstrated growth inhibition in ambient the mean growth index + standard deviation of the tumor volumes in the specific treatment group compared with a control group that received saline injection and was housed in ambient light. Direct (intratumoral) injection = 1 mg hematoporphyrin derivative (HPD)/cu cm into the tumor; intraperitoneal injection = 10 mg HPD/kg body weight. specifically, the number of macroscopic colonies formed from single cells following explant of the hematoporphyrin derivative (HPD) plus laser-treated tumors compared with control tumors that received saline injection and were exposed only to ambient light. Direct (intratumoral) injection = 1 mg HPD/cu cm; intraperitoneal injection = l0 mg HPD/kg body weight.
light (growth index = 0.34 ___ 0.40) and a 10-fold additional inhibition with laser photoirradiation (growth index = 0.03 _+ 0.01). These levels of inhibition produced by direct injection were significantly greater than the corresponding levels produced by intraperitoneal injection (p < 0.001).
Analogous results were obtained in the in vitro assay (Table 7) . For the intraperitoneally treated group, HPD in ambient room light produced a growth index of 0.60 ___ 0.20. The addition of laser light increased tumor inhibition (growth index = 0.005 _+ 0.04). Direct tumor injection of HPD produced a comparable growth inhibition in ambient room light (growth index = 0.53 ___ 0.27) and almost complete in vitro tumor cell growth inhibition when laser light was used (growth index = 0.0001 ___ 0.0001). Under ambient light there was no significant difference in the in vitro clonogenic assay between animals receiving direct injection and those receiving intraperitoneal injection (p > 0.5). For animals treated with laser light, direct injection produced more inhibition of cell growth than did intraperitoneal injection (p < 0.02).
H. Kostron, et al.
Discussion
Malignant gliomas are fatal in virtually all instances, and patients with these tumors have received only partial benefit from the currently available surgical, medical, and radiotherapeutic treatments. Therefore, alternative forms of therapy have piqued the interest of investigators in the field. Photoradiation therapy using the sensitizer HPD and an activating visible light source has been an attractive modality because of the relatively different retention properties of HPD for malignant tumors versus most normal tissues; this results in the selective destruction of these tumors with respect to the surrounding tissue upon photoirradiation. Human studies have been conducted with intravenous administration of HPD, but cutaneous phototoxicity has limited the sensitizer dosage in these patients. Moreover, incomplete passage through the blood-brain barrier and accumulation of HPD in normal brain have caused additional problems in planning the treatment of brain lesions. Thus, although parenterally administered HPD has been used to treat a small number of patients with gliomas, it has not had a major impact on their care.
We therefore decided to use this rat glioma model to study the possibility that direct injection of HPD into the tumor could produce a higher intratumoral level of sensitizer than that produced by comparable intraperitoneal injection, and that this higher HPD level could be activated to produce an increased inhibition of tumor cell growth. We recognize that intratumoral injection has been tried with other compounds (such as radioisotopes or cytostatic agents other than HPD) in order to circumvent the blood-brain barrier, to minimize systemic toxicity, or to provide higher concentrations than are possible with parenteral administration. ~H4'~6 However, the other compounds that have been tested lack the differential retention characteristics of HPD to tumor when compared with normal brain.
Our initial studies of HPD distribution utilized a rat gliosarcoma grown both in the subcutaneous space and in the cerebral parenchyma. Studies in these two anatomical areas are complementary. The intracerebral tumors are more closely related to the natural location of gliomas in humans, and thus allow for the testing of the HPD distribution in the brain relative to distance from the tumor as well as for testing the possible adverse effects of intracerebral HPD injection. However, because intracerebral tumors in rats are limited in size (3 to 6 mm in diameter) and because the volume cannot be readily measured on a daily basis, a subcutaneous tumor model was used. The amount of HPD injected intraperitoneally (10 mg/kg body weight) was chosen for comparability with other studies in the literature.
Preliminary studies of direct injection of HPD (data not shown) allowed for the selection of a dose (1 mg/ cu cm tumor volume) that would produce tissue levels within a range generally comparable to the parenterally administered dose. With this model, we have shown that the direct injection of HPD into subcutaneous gliomas produced an increase in the HPD content within the tumor while reducing the HPD level in normal tissues such as brain and skin when compared with intraperitoneal injection. Because the actual HPD level is related to the dose injected, an alternative and perhaps better way of analyzing these data is to compare the ratio of HPD in the tumor to the ratio of HPD in the normal tissue. At 48 hours after HPD injection of subcutaneous tumors the tumor:skin ratio was 1.4:1 for the intraperitoneal group versus 44:1 for the group receiving direct intraneoplastic injection. This suggests that direct tumor injection produced about a 30-fold increase in the tumor:skin ratio of HPD (Table 1) .
For intracerebral tumors ( Tables 3 and 4) that were tested at 48 hours after HPD injection, direct intraneoplastic injection provided a tumor:edematous adjacent brain ratio of 3:1 versus 1.3:1 for intraperitoneal injection. The tumor:ipsilateral hemisphere ratio was 13:1 for direct injection versus 2.6:1 for intraperitoneal administration. This suggests that the direct injection of HPD produced a two-to fivefold increase in HPD content in the brain tumor relative to surrounding normal brain over intraperitoneal injection. This increased ratio was even more marked when the HPD concentrations in the intracerebral tumors were compared to the contralateral hemisphere for direct intratumoral injection versus intraperitoneal injection of 3H-HPD.
Although others have observed that HPD does not effectively cross the blood-brain barrier following parenteral injection and have reported different concentrations from ours, ~8'9 we have noted the presence of HPD within the normal brain of rats after intraperitoneal injection. These HPD values within the normal brain are similar to those found by Rounds, et al. 15 In this series of experiments, we did not investigate whether the HPD was located intracellularly, was bound to the cellular membrane, or was in the interstitial tissue of the tumor. Furthermore, in vivo the intracellular:intercellular concentrations may vary from one anatomic locale to another, and these differences may be related to the clearance of HPD from the tissue. The time course studies (Table 3) show that direct tumor injection produces 11.25/~g 3H-HPD/gm tissue in the tumor at 24 hours. By 48 hours this drops to 57% of the 24-hour value, and at 6 days this decreases further to 19%. In contrast, the edematous brain not only contains one-third the HPD value in tumor at 24 and 48 hours, but it is entirely cleared by 6 days. One possible explanation is that the HPD in the tumor is predominantly intracellular, whereas the HPD in the edematous brain is located in the interstitial fluid. Another possibility is that HPD in the tumor is more tightly bound than HPD in the edematous brain. In either case, if neurotoxicity to brain adjacent to the tumor becomes a limiting factor in HPD-photoradiation therapy, our time course studies suggest that treatment at an interval longer than 48 hours following injection may be worthy of further investigation. Since direct injection of HPD negates the possible importance of the blood-brain barrier, this technique may display tumor celI-HPD uptake kinetics more closely similar to the in vitro exposure of tumor cells (in contrast to in vivo uptake kinetics4). Under in vitro conditions, cell uptake of HPD is immediate and very rapid, with a plateau after about 6 to 12 hours; loss of HPD from these cells only occurs because of dilution from cell division or from the removal of the extracellular HPD.I High concentrations of HPD in tissue may undergo a different photochemical reaction than do lower concentrations of HPD. Photoactivation of low concentrations of HPD mainly generates singlet oxygen. At much higher concentrations, HPD may sensitize cells in the absence of oxygen? Therefore, since large tumors may contain areas of focal hypoxia which can be refractory to ionizing radiation and other therapies, the high concentrations of HPD produced by direct injection may provide an additional therapeutic benefit.
Conclusions
We have used a transplantable rat gliosarcoma model to demonstrate that direct tumor injection both subcutaneously and intraeerebrally is well tolerated by the animals and provides a substantial increase in HPD concentration in the tumor relative to that in the normal brain and skin when compared to intraperitoneal injection. Moreover, both in vivo and in vitro assay systems demonstrate that the directly injected HPD causes more inhibition of tumor growth than does intraperitoneal injection when activated by light. We believe that direct tumor injection offers a potential method of treatment of gliomas and that it should be further explored in larger animal models.
